Letteratura scientifica selezionata sul tema "3CLpro"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "3CLpro".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "3CLpro":
Ziebuhr, John, Sonja Bayer, Jeff A. Cowley e Alexander E. Gorbalenya. "The 3C-Like Proteinase of an Invertebrate Nidovirus Links Coronavirus and Potyvirus Homologs". Journal of Virology 77, n. 2 (15 gennaio 2003): 1415–26. http://dx.doi.org/10.1128/jvi.77.2.1415-1426.2003.
Tsu, Brian V., Rimjhim Agarwal, Nandan S. Gokhale, Jessie Kulsuptrakul, Andrew P. Ryan, Elizabeth J. Fay, Lennice K. Castro et al. "Host-specific sensing of coronaviruses and picornaviruses by the CARD8 inflammasome". PLOS Biology 21, n. 6 (8 giugno 2023): e3002144. http://dx.doi.org/10.1371/journal.pbio.3002144.
Rawson, Jonathan M. O., Alice Duchon, Olga A. Nikolaitchik, Vinay K. Pathak e Wei-Shau Hu. "Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors". Viruses 13, n. 2 (24 gennaio 2021): 173. http://dx.doi.org/10.3390/v13020173.
Zhang, Jingjing, Yingpei Jiang, Chunxiu Wu, Dan Zhou, Jufang Gong, Tiejun Zhao e Zhigang Jin. "Development of FRET and Stress Granule Dual-Based System to Screen for Viral 3C Protease Inhibitors". Molecules 28, n. 7 (28 marzo 2023): 3020. http://dx.doi.org/10.3390/molecules28073020.
Sanachai, Kamonpan, Tuanjai Somboon, Patcharin Wilasluck, Peerapon Deetanya, Peter Wolschann, Thierry Langer, Vannajan Sanghiran Lee, Kittikhun Wangkanont, Thanyada Rungrotmongkol e Supot Hannongbua. "Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening". PLOS ONE 17, n. 6 (30 giugno 2022): e0269563. http://dx.doi.org/10.1371/journal.pone.0269563.
Glab-ampai, Kittirat, Kanasap Kaewchim, Thanatsaran Saenlom, Watayagorn Thepsawat, Kodchakorn Mahasongkram, Nitat Sookrung, Wanpen Chaicumpa e Monrat Chulanetra. "Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants". International Journal of Molecular Sciences 23, n. 12 (13 giugno 2022): 6587. http://dx.doi.org/10.3390/ijms23126587.
Ye, Gang, Xiaowei Wang, Xiaohan Tong, Yuejun Shi, Zhen F. Fu e Guiqing Peng. "Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376". Viruses 12, n. 2 (21 febbraio 2020): 240. http://dx.doi.org/10.3390/v12020240.
Chen, Chia-Nan, Coney P. C. Lin, Kuo-Kuei Huang, Wei-Cheng Chen, Hsin-Pang Hsieh, Po-Huang Liang e John T. A. Hsu. "Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)". Evidence-Based Complementary and Alternative Medicine 2, n. 2 (2005): 209–15. http://dx.doi.org/10.1093/ecam/neh081.
Rana, Shiwani, Prateek Kumar, Anchal Sharma, Sanjay Sharma, Rajanish Giri e Kalyan S. Ghosh. "Identification of Naturally Occurring Antiviral Molecules for SARS-CoV-2 Mitigation". Open COVID Journal 1, n. 1 (10 giugno 2021): 38–46. http://dx.doi.org/10.2174/2666958702101010038.
Wu, Jing, Bo Feng, Li-Xin Gao, Chun Zhang, Jia Li, Da-Jun Xiang, Yi Zang e Wen-Long Wang. "Synthesis and Biochemical Evaluation of 8H-Indeno[1,2-d]thiazole Derivatives as Novel SARS-CoV-2 3CL Protease Inhibitors". Molecules 27, n. 10 (23 maggio 2022): 3359. http://dx.doi.org/10.3390/molecules27103359.
Tesi sul tema "3CLpro":
Brier, Lucile. "Conception d'une stratégie de découverte de composés antiviraux contre les coronavirus : du criblage à l'optimisation d'inhibiteurs de la protéase 3CL du SARS-CoV-2". Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS031.
Coronaviruses are RNA viruses causing respiratory, enteric, hepatic and neurological diseases of varying severity in different species, including humans. Among them, seven can infect humans. HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1 strains cause mild respiratory tract infections. SARS-CoV, MERS-CoV, and SARS-CoV-2 are potentially fatal and have caused major outbreaks. Today, SARS-CoV-2 is still circulating but the vaccine strategy has significantly reduced the risks of hospitalization and death. Also, the first specific antiviral drug has been authorized on the market (Paxlovid™). Nevertheless, coronaviruses are viruses with a high mutation and recombination rate, therefore the probability of facing new epidemics is very high. Thus, there is a need to discover new therapies to treat COVID-19 but also to anticipate and prevent future epidemics. Thanks to its essential role in the viral replication cycle of coronaviruses and the lack of human homolog, the viral protease 3CL is a promising target for the development of anti-coronaviral compounds. Moreover, this protease is remarkably conserved among coronavirus species. The 3CLpro is then an interesting target for the design of broad-spectrum antivirals able to fight against SARS-CoV-2 but also against potential emerging coronaviruses. Thus, the objective of this thesis work was to develop a strategy to discover new non-peptidomimetic inhibitors of the 3CLpro of SARS-CoV-2 that are potent, selective and capable of exerting pan-inhibition on other coronavirus species. The first part of this thesis project consisted of developing and performing a high-throughput screening on the SARS-CoV-2 3CL protease, allowing the identification of several chemical series of interest. Further work focused on the optimization of two chemical series, reversible covalent inhibitors for the first one and non-covalent for the second one, whose chemotypes have not been described on the 3CL protease. In these two chemical series, more than 90 analogues have been synthesized with the aim of improving the potency on the target and establishing structure-activity relationships. Physicochemical and ADME properties in vitro, binding mode, selectivity towards human proteases, inhibition of 3CLpro from other coronaviruses and in cellulo antiviral activity were studied
Capitoli di libri sul tema "3CLpro":
Zhang, Jiapu. "3C-Like Protease (3CLpro)". In Springer Series in Biophysics, 33–159. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-36773-1_2.
Zhang, Jiapu. "3CLpro Binding with N3/Lopinavir/Ritonavir". In Springer Series in Biophysics, 457–77. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-36773-1_15.
Sims, A. C., X. T. Lu e M. R. Denison. "Expression, Purification, and Activity of Recombinant MHV-A59 3CLpro". In Advances in Experimental Medicine and Biology, 129–34. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5331-1_17.
Zhang, Jiapu. "3CLpro Dimer Binding with 7 HIV Inhibitors and Others". In Springer Series in Biophysics, 479–509. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-36773-1_16.
Hamill, Pamela, Martin Richer, Derek Hudson, Hongyan Xu e François Jean. "Novel Blue- and Red-Shifted Internally Quenched Fluorogenic Substrates for Continuous Monitoring of SARS-CoV 3CLpro". In Understanding Biology Using Peptides, 403–4. New York, NY: Springer New York, 2006. http://dx.doi.org/10.1007/978-0-387-26575-9_167.
Jayakumar, Manju Nidagodu, Jisha Pillai U., Moksha Mehta, Karanveer Singh, Eldhose Iype e Mainak Dutta. "Identification of Potential Inhibitors Against SARS-CoV-2 3CLpro, PLpro, and RdRP Proteins: An In-Silico Approach". In Advances in Computational Modeling and Simulation, 85–112. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7857-8_8.
"Peptidomimetic and Peptide-Derived Against 3CLpro from Coronaviruses". In Pharmaceuticals for Targeting Coronaviruses, a cura di Paulo Fernando da Silva Santos-Júnior, João Xavier de Araújo-Júnior e Edeildo Ferreira da Silva-Júnior, 158–88. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815051308122010007.
Hosseini, Fatemeh, Mehrdad Azin, Hamideh Ofoghi e Tahereh Alinejad. "Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential SARS-CoV-2 Viral Inhibitors". In Drug Repurposing - Molecular Aspects and Therapeutic Applications [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101395.
Ramos Tayt-Sohn, Victória. "Preparação in silico do alvo molecular 3Clpro do SARS-CoV-2". In Ciência Brasileira: Múltiplos olhares - Medicina, Saúde e Prevenção Volume 02. 2a ed. Brasil: Even3 Publicações, 2023. http://dx.doi.org/10.29327/cb-medicina-saude-e-prevencao-2.599858.
Torawane, Sarika Daulatrao, e Sarika Torwane. "Therapeutic Potential of Medicinal Plants in the Management and Treatment of Severe Acute Respiratory Syndrome 2 (SARS CoV-2 [COVID-19])". In Exploring Complementary and Alternative Medicinal Products in Disease Therapy, 225–67. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-7998-4120-3.ch010.
Atti di convegni sul tema "3CLpro":
Mondal, Kushal, e Sowmya Kamath S. "QSAR Classification Models for Predicting 3CLPro-protease Inhibitor Activity". In 2021 IEEE 4th International Conference on Computing, Power and Communication Technologies (GUCON). IEEE, 2021. http://dx.doi.org/10.1109/gucon50781.2021.9573896.
Фомина, А. Д., e Д. И. Осолодкин. "РАЗРАБОТКА МЕТОДА АНСАМБЛЕВОГО ДОКИНГА ИНГИБИТОРОВ ПРОТЕАЗЫ 3CLPRO SARS-COV-2". In MedChem-Russia 2021. 5-я Российская конференция по медицинской химии с международным участием «МедХим-Россия 2021». Издательство Волгоградского государственного медицинского университета, 2021. http://dx.doi.org/10.19163/medchemrussia2021-2021-322.
Lin, Xiaoli, Xuan Liu e Xiaolong Zhang. "Anti-3CLpro Molecular Design Based on the Model Constrained by Specific DTIs". In 2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2023. http://dx.doi.org/10.1109/bibm58861.2023.10385660.
Semenov, V. A., e L. B. Krivdin. "BENCHMARK CALCULATIONS OF 1H AND 13C NMR CHEMICAL SHIFTS IN THE SERIES OF NATURAL CANDIDATES AGAINST 3CLPRO OF SARS COV-2". In MedChem-Russia 2021. 5-я Российская конференция по медицинской химии с международным участием «МедХим-Россия 2021». Издательство Волгоградского государственного медицинского университета, 2021. http://dx.doi.org/10.19163/medchemrussia2021-2021-435.
Lan, Yuhao. "A Comparative Study of the Inhibitory Effects of Rheum palmatum L. and Isatis Indigotica Root, on 3CLpro from SARS-CoV-2 Using Both Cell-based and Cell-free Assay Models". In ICBET '21: 2021 11th International Conference on Biomedical Engineering and Technology. New York, NY, USA: ACM, 2021. http://dx.doi.org/10.1145/3460238.3461671.